Navigating regulatory crossroads: FSSAI vs CDSCO for nutraceuticals

Table: Categories of chemical compound-based nutraceuticals.

Antioxidants & polyphenols: Flavonoids, curcuminoids, and resveratrol, and other anti-inflammatory and antioxidants. Amino acids: Arginine, taurine, and glutamine. Lipids & fatty acids: Omega-3 fatty acids, conjugated linoleic acid, and phospholipids. Carbohydrate derivatives: Ascorbic acid and prebiotic oligosaccharides. Minerals & Vitamins: Vitamin A, B complex, C, D E & K. Essential minerals such as salts of calcium, iron, magnesium, zinc etc.

Nutraceuticals and patient safety
In India, patient safety concerns regarding nutraceuticals revolve around quality control, misleading claims, and lack of adverse effect monitoring. Some key concerns include:

Lack of clinical data: Often nutraceuticals are marketed without clinical trials, leading to risk of lack of efficacy and safety.

Adverse reactions: Certain formulations may cause adverse reactions and needs monitoring.

Misleading claims: Some manufacturers may make overstated health claims without adequate scientific data. 

Quality control related issues: The Food Safety and Standards Authority of India (FSSAI) has set regulations, but enforcement remains a challenge, leading to concerns about cross-contamination, microbial contamination and incorrect labelling.

Unknown contaminants: The manufacturing processes of nutraceuticals may involve the use of solvents and additives that may result in presence of contaminants, pesticides, and toxic chemicals. 

Fixed dose combinations: Some products on the market may contain excessively high doses of micronutrient blends, combining multiple vitamins and minerals beyond recommended levels. 

Some nutraceuticals may contain ingredients not listed on the label, and these ingredients sometimes may be unsafe. 

Global regulatory oversight of nutraceuticals
Globally, nutraceuticals are regulated differently. Some countries treat them as food products, while others enforce drug like safety and efficacy requirements. In the United States, nutraceuticals fall under Dietary Supplement Health and Education Act, requiring manufacturer’s responsibility for safety. The US FDA monitors adverse event reports and can direct recall of unsafe products from the market. Strict regulations prevent misleading health claims, ensuring scientific backing. Even though the US FDA does not approve dietary supplements, it has a role to regulate as follows: 

• Inspect manufacturing facilities to confirm compliance with applicable requirements.
• Monitor adverse event reports reported by companies, health care professionals, and consumers. 
• Investigate consumer complaints.
• If a product is found to be unsafe or doesn’t comply with the law, the US FDA can ensure the company brings the product into compliance, and direct the company to recall the product.

On the other hand, in the European Union, European Food Safety Authority, requires scientific validation for health claims before market entry and ensure ingredient safety. 

In Canada, Health Canada (Natural Health Products Directorate), requires clinical trials for high-risk nutraceuticals, evaluates possible interactions before approval and monitors adverse effects. In Australia, the therapeutic goods agency requires high-risk nutraceuticals to undergo pharmaceutical like testing, enforces GMP, and requires scientific substantiation for claims.  

While the above countries enforce stricter oversight, India’s FSSAI classifies nutraceuticals as food products, leading to more relaxed safety evaluation requirements.

FSSAI vs CDSCO for nutraceuticals
The debate over whether FSSAI should be replaced by CDSCO for nutraceutical regulations in India stems from concerns about consumer safety and enforcement. 

Some key reasons why this shift should be considered is listed below:

Overlap between food and drug regulations: Many nutraceuticals contain ingredients that are also used in pharmaceuticals, such as probiotics, vitamins and minerals. The lack of clear demarcation between therapeutic and nutritional usage. 

Stricter oversight under CDSCO: Unlike FSSAI, which primarily regulates food safety, CDSCO enforces GMP, clinical trials, and pharmacovigilance for pharmaceuticals. Bringing nutraceuticals under CDSCO could ensure better safety standards and efficacy testing.

Concerns over disease management claims: Some nutraceuticals are marketed with disease risk reduction claims, despite lacking the rigorous testing required for pharmaceuticals. This has raised concerns about misleading consumers and the potential misuse of these products.

Regulatory challenges and enforcement issues: The interchangeable usage of the same nutrient/ingredient at different doses for pharma and nutraceutical purposes has led to inconsistent enforcement.

Closing perspective 
The question of whether the CDSCO should be the licensing authority for chemical compound-based nutraceuticals is a complex regulatory topic. Currently, nutraceuticals fall under the FSSAI, which regulates them as food products rather than drugs. However, there has been discussion about shifting regulatory oversight to CDSCO to address concerns about safety, efficacy, and uniformity in enforcement.

For strengthening nutraceutical oversight, CDSCO might be a great fit for following reasons:

Chemical-based nutraceuticals often carry therapeutic claims, positioning them closer to pharmaceuticals, marketing it to specialist doctors and physicians. Strict regulations would ensure their safety and efficacy. 

Enhanced consumer protection, with CDSCO’s pharmacovigilance framework, adverse effects and misleading claims could be monitored more effectively, ensuring higher consumer safety and reducing the risk of unregulated formulations entering the market.

Many countries regulate high-potency nutraceuticals through their drug regulatory bodies rather than food safety authorities. Aligning Indian policies with international standards could improve market credibility, export potential and consumer trust.

However, there could be challenges of moving from FSSAI to CDSCO which includes:

Increased regulatory burden: CDSCO’s drug approval process is more stringent, which could slow down innovation in the nutraceutical sector.

Industry pushback: Many nutraceutical manufacturers prefer FSSAI’s more flexible framework, fearing higher costs and longer approval timelines under CDSCO.

Overlap in regulations: Some ingredients are used in both medicinal products and nutraceuticals, making it difficult to draw clear boundaries.

Given the critical concerns surrounding patient safety, including potential ingredient-ingredient interactions, appropriate dosage levels, and the accuracy of claims made by manufacturers, it is prudent to initially bring all chemical compound-based nutraceuticals under the purview of CDSCO. This regulatory shift would enhance oversight, ensuring greater consumer protection and mitigating risks associated with misleading or unsafe formulations.

Products approved by CDSCO could be promoted transparently through physicians, rather than being discreetly marketed as is often the case today. Establishing a clear and regulated framework for such promotions would ensure ethical dissemination of information, fostering trust between healthcare providers, patients, and manufacturers.

Conclusion
Pricing concerns in the nutraceutical industry have been gaining attention and the government may consider bringing these products under some form of price control to enhance affordability. Finally, it is appropriate to remember that a nutrient-rich diet remains the foundation of good health, there's simply no alternative to the power of whole foods. Nutraceuticals are not a replacement for a well-balanced, nutrient-dense diet. Instead, supplements serve to complement and enhance the benefits of wholesome diet.